Andrew Callos, EVP and Chief Commercial Officer at Cytokinetics Inc. ($CYTK), sold shares on the open market 18 times over the past year for a total of about $9.1 million. His most recent sale was on March 9, 2026. These transactions rank him 1,219th out of 11,678 insiders by total value sold, exceeding the average of $8.6 million across roughly 6 sales per insider. Callos made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 3639 | $65.00 | 66,004.0000 | 122,264,929 | 5.23% | 0.00% |
| March 17, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 5626 | $62.15 | 74,489.0000 | 122,264,929 | 7.02% | 0.00% |
| March 18, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 1930 | $62.07 | 78,185.0000 | 122,264,929 | 2.41% | 0.00% |
| March 17, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 2916 | $62.15 | 71,573.0000 | 122,264,929 | 3.91% | 0.00% |
| March 15, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Common Stock | 13320 | $0.00 | 81,824.0000 | 122,264,929 | 19.44% | 0.01% |
| March 15, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Incentive Stock Option (Right to Buy) | 1665 | $0.00 | 1,665.0000 | 122,264,929 | 9999.99% | 0.00% |
| March 15, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Non-Qualified Stock Option (Right to Buy) | 29480 | $0.00 | 29,480.0000 | 122,264,929 | 9999.99% | 0.02% |
| March 15, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Common Stock | 20646 | $0.00 | 68,504.0000 | 122,264,929 | 43.14% | 0.02% |
| March 16, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 1709 | $61.03 | 46,149.0000 | 122,264,929 | 3.57% | 0.00% |
| March 9, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 2582 | $60.72 | 47,858.0000 | 122,264,929 | 5.12% | 0.00% |
| March 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 11000 | $61.88 | 50,440.0000 | 122,264,929 | 17.90% | 0.01% |
| March 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 15000 | $61.87 | 61,440.0000 | 122,264,929 | 19.62% | 0.01% |
| March 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 11000 | $39.13 | 76,440.0000 | 122,264,929 | 16.81% | 0.01% |
| March 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 15000 | $23.26 | 65,440.0000 | 122,264,929 | 29.74% | 0.01% |
| March 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 11000 | $0.00 | 24,403.0000 | 122,264,929 | 31.07% | 0.01% |
| March 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 15000 | $0.00 | 69,000.0000 | 122,264,929 | 17.86% | 0.01% |
| March 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Incentive Stock Option (Right to Buy) | 886 | $0.00 | 0.0000 | 122,264,929 | 100.00% | 0.00% |
| March 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 886 | $61.62 | 50,440.0000 | 122,264,929 | 1.73% | 0.00% |
| March 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 886 | $37.63 | 51,326.0000 | 122,264,929 | 1.76% | 0.00% |
| Feb. 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 15000 | $23.26 | 65,440.0000 | 122,264,929 | 29.74% | 0.01% |
| Feb. 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 15000 | $0.00 | 84,000.0000 | 122,264,929 | 15.15% | 0.01% |
| Feb. 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 15000 | $61.93 | 50,440.0000 | 122,264,929 | 22.92% | 0.01% |
| Feb. 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 886 | $37.63 | 51,326.0000 | 122,264,929 | 1.76% | 0.00% |
| Feb. 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 886 | $62.10 | 50,440.0000 | 122,264,929 | 1.73% | 0.00% |
| Feb. 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Incentive Stock Option (Right to Buy) | 886 | $0.00 | 886.0000 | 122,264,929 | 50.00% | 0.00% |
| Jan. 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 15000 | $23.26 | 65,440.0000 | 122,264,929 | 29.74% | 0.01% |
| Jan. 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 15000 | $0.00 | 99,000.0000 | 122,264,929 | 13.16% | 0.01% |
| Jan. 5, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 15000 | $60.28 | 50,440.0000 | 122,264,929 | 22.92% | 0.01% |
| Jan. 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Incentive Stock Option (Right to Buy) | 885 | $0.00 | 1,772.0000 | 122,264,929 | 33.31% | 0.00% |
| Jan. 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 885 | $63.16 | 50,440.0000 | 122,264,929 | 1.72% | 0.00% |
| Jan. 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 885 | $37.63 | 51,325.0000 | 122,264,929 | 1.75% | 0.00% |
| Jan. 2, 2026 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 913 | $62.09 | 50,440.0000 | 122,264,929 | 1.78% | 0.00% |
| Dec. 29, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 1809 | $62.44 | 51,353.0000 | 122,264,929 | 3.40% | 0.00% |
| Dec. 22, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | F | Common Stock | 675 | $62.72 | 53,162.0000 | 122,264,929 | 1.25% | 0.00% |
| Dec. 22, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Common Stock | 1588 | $0.00 | 53,837.0000 | 122,264,929 | 3.04% | 0.00% |
| Dec. 22, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Common Stock | 1589 | $0.00 | 52,249.0000 | 122,264,929 | 3.14% | 0.00% |
| Dec. 8, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 1042 | $65.96 | 50,660.0000 | 122,264,929 | 2.02% | 0.00% |
| Dec. 8, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 1042 | $39.13 | 51,702.0000 | 122,264,929 | 2.06% | 0.00% |
| Dec. 8, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 1042 | $0.00 | 35,403.0000 | 122,264,929 | 2.86% | 0.00% |
| Dec. 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 15858 | $37.63 | 92,518.0000 | 122,264,929 | 20.69% | 0.01% |
| Dec. 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 10628 | $37.63 | 103,146.0000 | 122,264,929 | 11.49% | 0.01% |
| Dec. 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 52486 | $65.95 | 50,660.0000 | 122,264,929 | 50.89% | 0.04% |
| Dec. 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 15000 | $0.00 | 114,000.0000 | 122,264,929 | 11.63% | 0.01% |
| Dec. 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 11000 | $0.00 | 36,445.0000 | 122,264,929 | 23.18% | 0.01% |
| Dec. 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 15858 | $0.00 | 15,857.0000 | 122,264,929 | 50.00% | 0.01% |
| Dec. 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Incentive Stock Option (Right to Buy) | 10628 | $0.00 | 2,657.0000 | 122,264,929 | 80.00% | 0.01% |
| Dec. 3, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | F | Common Stock | 1368 | $65.02 | 50,660.0000 | 122,264,929 | 2.63% | 0.00% |
| Dec. 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 15000 | $23.26 | 65,660.0000 | 122,264,929 | 29.61% | 0.01% |
| Dec. 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 11000 | $39.13 | 76,660.0000 | 122,264,929 | 16.75% | 0.01% |
| June 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 8659 | $32.04 | 52,028.0000 | 118,410,689 | 14.27% | 0.01% |
| May 5, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 4002 | $36.68 | 60,687.0000 | 118,410,689 | 6.19% | 0.00% |
| April 7, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 2886 | $35.78 | 64,689.0000 | 118,410,689 | 4.27% | 0.00% |
| March 14, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Common Stock | 32687 | $0.00 | 70,350.0000 | 118,410,689 | 86.79% | 0.03% |
| March 14, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Incentive Stock Option (Right to Buy) | 2749 | $0.00 | 2,749.0000 | 118,410,689 | 9999.99% | 0.00% |
| March 14, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Non-Qualified Stock Option (Right to Buy) | 47593 | $0.00 | 47,593.0000 | 118,410,689 | 9999.99% | 0.04% |
| March 17, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 2775 | $44.38 | 34,888.0000 | 118,410,689 | 7.37% | 0.00% |
| March 17, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 20900 | $23.26 | 58,563.0000 | 118,410,689 | 55.49% | 0.02% |
| March 17, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 20900 | $45.14 | 37,663.0000 | 118,410,689 | 35.69% | 0.02% |
| March 17, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 20900 | $0.00 | 129,000.0000 | 118,410,689 | 13.94% | 0.02% |
| March 14, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Common Stock | 100 | $23.26 | 37,763.0000 | 118,410,689 | 0.27% | 0.00% |
| March 14, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 100 | $45.00 | 37,663.0000 | 118,410,689 | 0.26% | 0.00% |
| March 14, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | M | Non-Qualified Stock Option (Right to Buy) | 100 | $0.00 | 149,900.0000 | 118,410,689 | 0.07% | 0.00% |
| March 13, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 26771 | $43.62 | 37,663.0000 | 118,410,689 | 41.55% | 0.02% |
| March 6, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 3341 | $43.27 | 64,434.0000 | 118,410,689 | 4.93% | 0.00% |
| March 3, 2025 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | S | Common Stock | 1114 | $42.88 | 67,775.0000 | 118,410,689 | 1.62% | 0.00% |
| Dec. 3, 2024 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Common Stock | 3176 | $0.00 | 67,063.0000 | 0 | 4.97% | 0.00% |
| Dec. 3, 2024 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | F | Common Stock | 1351 | $51.51 | 65,712.0000 | 0 | 2.01% | 0.00% |
| Dec. 3, 2024 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Common Stock | 3177 | $0.00 | 68,889.0000 | 0 | 4.83% | 0.00% |
| March 14, 2024 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Common Stock | 16941 | $0.00 | 63,887.0000 | 0 | 36.09% | 0.00% |
| March 14, 2024 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Non-Qualified Stock Option (Right to Buy) | 18346 | $0.00 | 18,346.0000 | 0 | 9999.99% | 0.00% |
| March 14, 2024 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Incentive Stock Option (Right to Buy) | 1224 | $0.00 | 1,224.0000 | 0 | 9999.99% | 0.00% |
| March 4, 2024 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | F | Common Stock | 2202 | $67.68 | 52,049.0000 | 0 | 4.06% | 0.00% |
| March 6, 2024 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | F | Common Stock | 5103 | $66.88 | 46,946.0000 | 0 | 9.80% | 0.00% |
| March 6, 2023 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Common Stock | 30000 | $0.00 | 53,683.0000 | 0 | 126.67% | 0.00% |
| March 6, 2023 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Incentive Stock Option (Right to Buy) | 2555 | $0.00 | 2,555.0000 | 0 | 9999.99% | 0.00% |
| March 6, 2023 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | A | Non-Qualified Stock Option (Right to Buy) | 47445 | $0.00 | 47,445.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2023 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | F | Common Stock | 2202 | $39.60 | 23,683.0000 | 0 | 8.51% | 0.00% |
| Feb. 16, 2023 | CYTOKINETICS INC | $CYTK | Callos Andrew | EVP, Chief Commercial Officer | F | Common Stock | 969 | $44.13 | 25,885.0000 | 0 | 3.61% | 0.00% |